An observational study in Treatment Resistant Depression, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Washington University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Depressive Disorder, Treatment-Resistant by Washington University School of Medicine — 3 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Washington University School of Medicine.
Among the 12 studies in Depressive Disorder, Treatment-Resistant by Washington University School of Medicine, this one is one of 3 that started in 2023, is the only observational one, and was the 10th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →3 of the 12 studies in Depressive Disorder, Treatment-Resistant by Washington University School of Medicine are open now, in 2 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–65 · Healthy volunteers
Washington University School of Medicine · Sites in United States, Canada
Ages 60+
By country, each count listing its studies:
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 73 across 50 observational studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 25 across the 11 interventional studies, 50 across the 1 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
4 of the studies in Depressive Disorder, Treatment-Resistant by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02994433Washington University School of MedicineNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits | 2027-04-30 |
| NCT04451135Washington University School of MedicineCET- REM (Correlating ECT Response to EEG Markers) | 2027-06 |
| NCT05905705Washington University School of MedicineDisruptions of Brain Networks and Sleep by Electroconvulsive Therapy | 2027-07-31 |
| NCT05838560Washington University School of MedicineDasatinib Plus Quercetin for Accelerated Aging in Mental Disorders | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Depressive Disorder, Treatment-Resistant by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
Graph-based network analyses of electroencephalographic (EEG) signals allow characterization of functional networks. The robustness of local networks to disruption is quantified as local efficiency (Elocal), while network integration is quantified as global information transfer (Eglobal).
Aim 1: Assess relationships between sleep slow-wave activity (SWA) and awake Elocal over the course of ECT.
Aim 2: Quantify relationships between depression severity and awake Elocal over the course of ECT.
Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
High-density EEG will be acquired during resting wakefulness before each ECT session.
Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
Slow wave activity (SWA) during non-rapid eye movement sleep (NREM) stage N2/N3
Total power of EEG slow waves per minute present during N2/N3 sleep
Time frame: Up to 4 weeks during patients ECT treatment course
Graph-based neural connectivity measure of local efficiency of information transfer (Elocal) during wakefulness
Elocal will be calculated as the average inverse shortest path length among neighbors of a node within the network. Nodes will be constructed based on 5-minute recordings of eyes closed wakefulness theta band (4-8 Hz) EEG.
Time frame: Up to 4 weeks during patients ECT treatment course
Graph-based neural connectivity measure of global information transfer (Eglobal) during ECT-induced seizure
Eglobal will be calculated as the average inverse shortest path length between node pairs in the networks. Nodes will be constructed based on ECT-induced seizure EEG data within the alpha band (8-13 Hz).
Time frame: Up to 4 weeks during patients ECT treatment course
Plan to share: Undecided
Started Mar 2023 (actual). Primary completion is estimated for Jul 2027, 52 months after the start.
Of 33 observational studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's planned 52 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Washington University School of Medicine →